Effects of cannabis use on body mass, fasting glucose and lipids during the first 12  months of treatment in schizophrenia spectrum disorders

In this study we investigated changes in body mass index (BMI), fasting blood glucose and lipids, and rates of metabolic syndrome risk factors in cannabis users vs. non-users in 109 minimally treated patients with first-episode schizophrenia, schizophreniform or schizo-affective disorder who were treated according to a standardized treatment regime with depot antipsychotic medication over 12  months.

Source: Schizophrenia Research - March 6, 2018 Category: Psychiatry Authors: F. Scheffler, S. Kilian, B. Chiliza, L. Asmal, L. Phahladira, S. du Plessis, M. Kidd, R.M. Murray, M. Di Forti, S. Seedat, R. Emsley Source Type: research